Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs McKesson Corporation — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.81 (market cap $8.88B), while McKesson Corporation trades at $992.58 (market cap $113.86B). The key difference: McKesson Corporation is far larger — about 12.8× Kymera Therapeutics Inc. Common Stock's market cap, and McKesson Corporation pays a 0.39% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and McKesson Corporation for 74 Days on average.
| KYMR | MCK | |
|---|---|---|
Market Cap | $8.88B | $113.86B |
Volume | 1,028,790 | 767,917 |
Sector | Health | Health |
52-Week High | $127.31 | $995.69 |
52-Week Low | $55.80 | $725.17 |
Typical Hold Time | 0 Days | 74 Days |
Enterprise Value | $8.27B | $120.40B |
Dividend Yield | — | 0.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MCK trades at $961.88, up 0.64% today, showing strong momentum with three consecutive earnings beats and a bullish technical outlook. The stock benefits from robust revenue growth reaching $359.1B in 2025 and positive sentiment from the recent CVS Health partnership extension through 2032. Analyst consensus remains strongly bullish with 81% buy ratings and a $956.43 price target, though the current price slightly exceeds this target.
MCK presents a compelling investment case with solid fundamentals and growth trajectory, though investors should monitor margin pressures and competitive dynamics. The company's strong cash flow generation and institutional support provide stability, while technical indicators suggest near-term resistance around $967-$978 levels could limit immediate upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
